.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,304,078

« Back to Dashboard

Claims for Patent: 7,304,078

Title:Thrombin receptor antagonists
Abstract: Heterocyclic-substituted tricyclics of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond; n is 0 2; Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14; R.sup.13 and R.sup.14 are independently selected from (C.sub.1 C.sub.6)alkyl, (C.sub.3 C.sub.8)cycloalkyl, --OH, (C.sub.1 C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1 C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3 6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Inventor(s): Chackalamannil; Samuel (Califon, NJ), Greenlee; William J. (Teaneck, NJ), Wang; Yuguang (North Brunswick, NJ), Wu; Wenxue (Princeton Junction, NJ), Veltri; Enrico P. (Princeton, NJ), Xia; Yan (Edison, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/412,982
Patent Claims: 1. A compound of the following formula: ##STR00153## or a pharmaceutically acceptable isomer, salt or solvate thereof.

2. A compound of the following formula: ##STR00154## or a pharmaceutically acceptable isomer thereof.

3. A compound of the following formula: ##STR00155## or a pharmaceutically acceptable salt thereof.

4. A bisulfate salt of a compound of the following formula: ##STR00156##

5. A compound of the following formula: ##STR00157## or a pharmaceutically acceptable solvate thereof.

6. A compound of the following formula: ##STR00158##

7. A pharmaceutical composition comprising an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1, and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising an effective amount of a compound or a pharmaceutical acceptable isomer thereof according to claim 2, and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising an effective amount of a compound or a pharmaceutically acceptable salt thereof salt thereof according to claim 3, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising an effective amount of the bisulfate salt according to claim 4, and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5, and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising an effective amount of the compound according to claim 6, and a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1, and one or more additional cardiovascular agents selected from the group consisting of aspirin and clopidogrel bisulfate.

14. A pharmaceutical composition comprising an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2, and one or more additional cardiovascular agents selected from the group consisting of aspirin and clopidogrel bisulfate.

15. A pharmaceutical composition comprising an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3, and one or more additional cardiovascular agents selected from the group consisting of aspirin and clopidogrel bisulfate.

16. A pharmaceutical composition comprising an effective amount of the bisulfate salt according to claim 4, and one or more additional cardiovascular agents selected from the group consisting of aspirin and clopidogrel bisulfate.

17. A pharmaceutical composition comprising an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5, and one or more additional cardiovascular agents selected from the group consisting of aspirin and clopidogrel bisulfate.

18. A pharmaceutical composition comprising an effective amount of the compound according to claim 6, and one or more additional cardiovascular agents selected from the group consisting of aspirin and clopidogrel bisulfate.

19. A method of treating thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolic stroke, peripheral vascular diseases, or cerebral ischemia comprising administering to a mammal an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1.

20. A method of treating thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolic stroke, peripheral vascular diseases, or cerebral ischemia comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2.

21. A method of treating thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolic stroke, peripheral vascular diseases, or cerebral ischemia comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3.

22. A method of treating thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolic stroke, peripheral vascular diseases, or cerebral ischemia comprising administering to a mammal an effective amount of the bisulfate salt according to claim 4.

23. A method of treating thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolic stroke, peripheral vascular diseases, or cerebral ischemia comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5.

24. A method of treating thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolic stroke, peripheral vascular diseases, or cerebral ischemia comprising administering to a mammal an effective amount of the compound according to claim 6.

25. A method of treating thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolytic stroke, peripheral vascular diseases, or cerebral ischemia comprising administering to a mammal an effective amount of a pharmaceutical composition of any of claims 7-18.

26. A method of treating thrombosis comprising administering to a mammal an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1.

27. A method of treating atherosclerosis comprising administering to a mammal an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1.

28. A method of treating myocardial infarction comprising administering to a mammal an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1.

29. A method of treating thrombotic stroke comprising administering to a mammal an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1.

30. A method of treating a peripheral vascular disease comprising administering to a mammal an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1.

31. A method of treating thrombosis comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2.

32. A method of treating atherosclerosis comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2.

33. A method of treating myocardial infarction comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2.

34. A method of treating thrombotic stroke comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2.

35. A method of treating a peripheral vascular disease comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2.

36. A method of treating thrombosis comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3.

37. A method of treating atherosclerosis comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3.

38. A method of treating myocardial infarction comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3.

39. A method of treating thrombotic stroke comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3.

40. A method of treating a peripheral vascular disease comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3.

41. A method of treating thrombosis comprising administering to a mammal an effective amount of a bisulfate salt according to claim 4.

42. A method of treating atherosclerosis comprising administering to a mammal an effective amount of a bisulfate salt according to claim 4.

43. A method of treating myocardial infarction comprising administering to a mammal an effective amount of a bisulfate salt according to claim 4.

44. A method of treating thrombotic stroke comprising administering to a mammal an effective amount of a bisulfate salt according to claim 4.

45. A method of treating a peripheral vascular disease comprising administering to a mammal an effective amount of a bisulfate salt according to claim 4.

46. A method of treating thrombosis comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5.

47. A method of treating atherosclerosis comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5.

48. A method of treating myocardial infarction comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5.

49. A method of treating thrombotic stroke comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5.

50. A method of treating a peripheral vascular disease comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5.

51. A method of treating thrombosis comprising administering to a mammal an effective amount of a compound according to claim 6.

52. A method of treating atherosclerosis comprising administering to a mammal an effective amount of a compound according to claim 6.

53. A method of treating myocardial infarction comprising administering to a mammal an effective amount of a compound according to claim 6.

54. A method of treating thrombotic stroke comprising administering to a mammal an effective amount of a compound according to claim 6.

55. A method of treating a peripheral vascular disease comprising administering to a mammal an effective amount of a compound according to claim 6.

56. A method of treating thrombosis comprising administering to a mammal an effective amount of a pharmaceutical composition of any of claims 7-18.

57. A method of treating atherosclerosis comprising administering to a mammal an effective amount of a pharmaceutical composition of any of claims 7-18.

58. A method of treating myocardial infarction comprising administering to a mammal an effective amount of a pharmaceutical composition of any of claims 7-18.

59. A method of treating thrombotic stroke comprising administering to a mammal an effective amount of a pharmaceutical composition of any of claims 7-18.

60. A method of treating a peripheral vascular disease comprising administering to a mammal an effective amount of a pharmaceutical composition of any of claims 7-18.

61. A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a compound, or a pharmaceutically acceptable isomer, salt or solvate thereof, according to claim 1.

62. A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable isomer thereof according to claim 2.

63. A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 3.

64. A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a bisulfate salt according to claim 4.

65. A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a compound or a pharmaceutically acceptable solvate thereof according to claim 5.

66. A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a compound according to claim 6.

67. A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a pharmaceutical composition of any of claims 7-18.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc